Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (DVAX) delivers innovative vaccine solutions through cutting-edge immunological research and strategic commercialization. This news hub provides investors and healthcare professionals with essential updates on the biopharmaceutical leader's clinical developments, regulatory milestones, and market activities.
Track all critical DVAX updates in one place: Access press releases covering vaccine trial progress, FDA decisions, financial results, and partnership announcements. Our curated feed includes updates on HEPLISAV-B commercialization, CpG 1018 adjuvant applications, and pipeline developments across infectious disease and cancer immunotherapy programs.
Key coverage areas: Regulatory submissions for new vaccine candidates, quarterly earnings reports, manufacturing expansions, and scientific presentations. Content is rigorously verified to ensure accuracy for both professional investors and those monitoring public health advancements.
Bookmark this page for continuous access to Dynavax's official communications and analysis of strategic initiatives shaping the future of preventive healthcare. Check regularly for developments impacting vaccine accessibility and immunological innovation.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to supply its CpG 1018 adjuvant for COVID-19 vaccines. CEPI will provide up to $99 million in funding through a forgivable loan to support the manufacturing of CpG 1018. This agreement aims to enhance vaccine efficacy and ensure equitable access globally. The stockpiled adjuvant will be available for CEPI grantees, with reimbursement obligations tied to sales. This collaboration underscores CpG 1018's potential role in addressing the pandemic.
Clover Biopharmaceuticals and Dynavax Technologies (DVAX) announced plans to initiate a global Phase 2/3 efficacy trial for the S-Trimer COVID-19 vaccine candidate in the first half of 2021. This trial, supported by CEPI, aims for interim efficacy results mid-2021. Clover's vaccine showed promising results in Phase 1, generating high neutralizing antibodies with a favorable safety profile. Clover aims to produce up to 1 billion doses annually. The partnership with GSK evaluating an adjuvant has been discontinued, but both companies remain committed to combating the pandemic.
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation announced the dosing of the first participant in the Phase 2 clinical trial for MVC-COV1901, a COVID-19 vaccine candidate. The trial, which aims to enroll 3,700 healthy participants aged 20 and above, will assess the safety and immunogenicity of the vaccine, which is a subunit vaccine using recombinant S-2P antigen and CpG 1018 adjuvant. Preliminary Phase 1 data indicated a good safety profile and promising immunogenicity. The trial's approval by Taiwan FDA marks a significant step forward in addressing COVID-19.
Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Kelly MacDonald as Senior Vice President and Chief Financial Officer, effective March 1, 2021. Her predecessor, Michael Ostrach, is retiring after 14 years but will remain as an advisor. MacDonald brings extensive experience from Ironwood Pharmaceuticals, where she was Chief Accounting Officer. She holds an MBA and is a Certified Public Accountant. This leadership change is expected to support Dynavax's strategic growth in developing vaccines for infectious diseases.
Dynavax Technologies Corporation (Nasdaq: DVAX) reported positive final immunogenicity and interim safety results from a clinical trial of its hepatitis B vaccine, HEPLISAV-B, in patients undergoing hemodialysis. The study included 119 patients, achieving a seroprotection rate of 89.3% with no safety concerns noted. The trial suggests HEPLISAV-B can offer a 4-dose regimen, potentially requiring fewer doses than the current standard of care. Full safety results are anticipated by the end of 2021.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. The on-demand presentation will start on January 11 at 6:00 a.m. E.T., accessible via the company's website. Dynavax focuses on developing and commercializing vaccines, with its first product, HEPLISAV-B®, approved in the U.S. for hepatitis B prevention in adults. The company is also advancing vaccine adjuvants for COVID-19 and other diseases.
On December 23, 2020, Serum Institute of India (SIIPL) and Dynavax Technologies Corporation (Nasdaq: DVAX) announced the dosing of the first participants in their Phase 1/2 clinical trial for a COVID-19 vaccine. The trial evaluates SIIPL's vaccine candidate, using Dynavax's CpG 1018 adjuvant, aiming to boost the immune response. The Phase 1 part will enroll 39 volunteers, leading to up to 216 subjects in Phase 2. SIIPL aims to leverage its manufacturing capabilities for affordable global vaccine supply amidst the pandemic.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for HEPLISAV-B, recommending marketing authorization for this hepatitis B vaccine in adults 18 and older. The recommendation is based on favorable safety and immunogenicity data from three Phase 3 trials. If approved by the European Commission in early 2021, HEPLISAV-B will enhance patient compliance with its two-dose regimen, addressing significant challenges in hepatitis B vaccination.
Clover Biopharmaceuticals has reported positive Phase 1 clinical trial results for its COVID-19 S-Trimer vaccine candidates, demonstrating strong immune responses and a favorable safety profile in 150 participants. Both GSK and Dynavax adjuvants showed 100% seroconversion for neutralizing antibodies in adult groups. The vaccine's stability allows for storage at refrigeration temperatures, facilitating global distribution. Clover plans to begin Phase 2/3 efficacy studies in December 2020 and initiate a pivotal trial with Dynavax in early 2021, aiming to produce over one billion doses annually.
Dynavax Technologies Corporation (NASDAQ: DVAX) will have CEO Ryan Spencer participate in a virtual fireside chat at the 3rd Annual Evercore Virtual ISI HealthCONx Conference on December 3, 2020, at 10:05 a.m. E.T. The event will be accessible via the company's website under the 'Events & Presentations' section. A replay will be available for 30 days post-event. Dynavax is developing innovative vaccines, including its first commercial product, HEPLISAV-B, aimed at preventing hepatitis B infections in adults.
